{"id":13660,"date":"2024-05-14T09:12:01","date_gmt":"2024-05-14T16:12:01","guid":{"rendered":"https:\/\/depts.washington.edu\/diabetes\/?p=13660"},"modified":"2024-05-14T09:12:01","modified_gmt":"2024-05-14T16:12:01","slug":"study-of-t1d-in-adults-provides-new-insights-2-2-2-2-2-2","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/diabetes\/study-of-t1d-in-adults-provides-new-insights-2-2-2-2-2-2\/","title":{"rendered":"Poll: GLP-1 drugs have been used by 1 in 8 US adults"},"content":{"rendered":"<section class=\"kc-elm kc-css-171186 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-997785 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-799127 kc_text_block\">\n<p class=\"MsoNormal\" style=\"line-height: 18.75pt;\"><span style=\"font-size: 15.3333px;\">A Kaiser Family Foundation <a href=\"https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/\">poll<\/a> found that an estimated 1 in 8 US adults has taken a GLP-1 class drug to treat weight loss and obesity-related conditions, with 6% of poll respondents stating they were currently using Eli Lilly and Co.&#8217;s obesity drug Zepbound or Novo Nordisk&#8217;s Ozempic for diabetes or Wegovy for weight loss. The poll also showed an increased awareness about such treatments, as well as their popularity, despite recent intermittent supply shortages of these drugs.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: 18.75pt;\"><span style=\"font-size: 15.3333px;\">\u00a0Full Story: <a href=\"https:\/\/newsletter.smartbrief.com\/redirect.action?link=https%3A%2F%2Fwww.reuters.com%2Fworld%2Fus%2Froughly-1-8-us-adults-have-taken-glp-1-drugs-like-wegovy-poll-shows-2024-05-10%2F&amp;encoded=rXouCehuiFDCdDzWCigmqPCicNePeo\">Reuters<\/a> (5\/10)\u00a0\u00a0<\/span><\/p>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"link","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-13660","post","type-post","status-publish","format-link","hentry","category-diabetes-related-news","post_format-post-format-link"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/comments?post=13660"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13660\/revisions"}],"predecessor-version":[{"id":13661,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13660\/revisions\/13661"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/media?parent=13660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/categories?post=13660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/tags?post=13660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}